Article

Topigen Pharmaceuticals, Novagali Pharma to collaborate on drug-delivery system

Topigen Pharmaceuticals and Novagali Pharma will collaborate on products designed to improve the bioadhesion and efficacy of RNA-targeting therapeutics delivered to the nasal membrane and ocular surface.

Key Points

Montréal-Two biopharmaceutical companies will collaborate on products designed to improve the bioadhesion and efficacy of RNA-targeting therapeutics delivered to the nasal membrane and ocular surface.

Topigen Pharmaceuticals Inc. of Montréal and Novagali Pharma SA of Evry, France, also announced a cross-license agreement. Under terms of the agreement, Novagali will receive an exclusive worldwide license to develop and commercialize an ophthalmic product based on Topigen's multi-targeted, RNA-targeting platform technology for the treatment and prevention of allergic eye diseases. Topigen will receive an exclusive license to Novagali's topical delivery technology (Novasorb) for use in formulating and developing an RNA-targeted therapy for respiratory conditions such as allergic rhinitis.

Under their agreement, each company will develop the delivery system, which provides improved retention time for therapeutic compounds in the cornea and conjunctiva, as well as within the nose. Novagali will develop it for the prevention of eye diseases.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.